Our top pick for
Sensei Biotherapeutics, Inc is a biotechnology business based in the US. Sensei Biotherapeutics shares (SNSE) are listed on the NASDAQ and all prices are listed in US Dollars. Sensei Biotherapeutics employs 30 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$11.75 - $26.50|
|50-day moving average||$14.71|
|200-day moving average||$16.12|
|Wall St. target price||$29.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-103.29%|
|Return on equity TTM||0%|
|Market capitalisation||$427 million|
TTM: trailing 12 months
There are currently 571,532 Sensei Biotherapeutics shares held short by investors – that's known as Sensei Biotherapeutics's "short interest". This figure is 40.3% up from 407,446 last month.
There are a few different ways that this level of interest in shorting Sensei Biotherapeutics shares can be evaluated.
Sensei Biotherapeutics's "short interest ratio" (SIR) is the quantity of Sensei Biotherapeutics shares currently shorted divided by the average quantity of Sensei Biotherapeutics shares traded daily (recently around 207076.8115942). Sensei Biotherapeutics's SIR currently stands at 2.76. In other words for every 100,000 Sensei Biotherapeutics shares traded daily on the market, roughly 2760 shares are currently held short.
To gain some more context, you can compare Sensei Biotherapeutics's short interest ratio against those of similar companies.
However Sensei Biotherapeutics's short interest can also be evaluated against the total number of Sensei Biotherapeutics shares, or, against the total number of tradable Sensei Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sensei Biotherapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Sensei Biotherapeutics shares in existence, roughly 20 shares are currently held short) or 0.0272% of the tradable shares (for every 100,000 tradable Sensei Biotherapeutics shares, roughly 27 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sensei Biotherapeutics.
Find out more about how you can short Sensei Biotherapeutics stock.
We're not expecting Sensei Biotherapeutics to pay a dividend over the next 12 months.
Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.